TRX-105 is a known small molecule developed for new therapeutic indications of treating and alleviating symptoms of various types of colitis. In animal disease model, TRX-105 showed greater effects than reference drug, mesalazine in reducing inflammatory colon swelling and intestinal ulceration, while restoring damage of intestinal membrane. TRX-105 is one of few products capable of repairing damaged intestine membrane caused by colitis. TRX-105, with its synergistic effect via different mechanism of actions, can provide greater medical benefits to patients with colitis and enterocolitis, including acute intestinal colitis, immune-related colitis and chemotherapy-induced colitis.